BC Week In Review | Oct 5, 2015
Clinical News

CAR-T EGFR: Phase I/II data

Data from 24 patients with EGFR-expressing advanced relapsed/refractory solid tumors in an open-label, Chinese Phase I/II trial showed that CBM-EGFR.1 was well tolerated and led to a disease control rate (DCR) of 79%. In 5...
Items per page:
1 - 1 of 1